Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4352W HIGH $2.79
Volume
17.80 K
Value Traded
22.07 K
Short % Float
1.3%
-1.69%Week
-15.66%1 Month
-66.38%3 Month
-62.91%6 Month
-99.99%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.27 M
EPS (TTM)
-1.05
P/E Ratio
-
Ent. Value
-2.76 M
Total Shares
2.76 M
Float Shares
2.76 M
Insiders
0.02%
Institutions
0.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BBLG Catalyst Timeline
Dated clinical, regulatory and corporate events for Bone Biologics Corp
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bone Biologics Corp
21Total events
7Upcoming
1Tier-1 (high impact)
2025 to 2027Coverage
Upcoming catalysts 2
Event history 10
▲Trial InitiationNB1Trial
Six hospital sites in Australia under agreement to participate
degenerative disc diseasesource ↗
▲Enrollment UpdateNB1Trial
Six additional Australian hospital sites under agreement for NB1 pilot trial, doubling participating centers
degenerative disc disease (DDD) undergoing transforaminal lumbar interbody fusion (TLIF)source ↗
▲Manufacturing MilestonerhNELL-1CMC / Inspection
Validated shelf life of rhNELL-1 extended to 32 months
▲Manufacturing MilestoneNB1CMC / Inspection
Validated shelf life of rhNELL-1 extended to 29 months
spinal fusionsource ↗
▲Manufacturing MilestonerhNELL-1CMC / Inspection
Validated shelf life of rhNELL-1 extended to 29 months
▲Manufacturing MilestonerhNELL-1CMC / Inspection
Validated shelf life of rhNELL-1 extended to 24 months
Past FDA Catalysts and PDUFA Decisions
How BBLG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$2M
Pipeline Value
Not rated
Valuation Signal
3
Drugs Scored
1.9x
rNPV / MCap
Top 53%
Micro Cap(rank 349 of 658)
Percentile Rank
Bone Biologics Corp faces pipeline headwinds (35/100), with $653M risk-adjusted pipeline value, led by JTA-004 in Symptomatic Osteoarthritis of the Knee (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| JTA-004 Small moleculeCompletedNCT04333160 | Symptomatic Osteoarthritis of the Knee | Phase 3 | COMPLETED | 746 | Dec 9, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every BBLG program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Walsh Deina HOfficer (Chief Financial Officer) | Buy | 8,000 15,000 held | $0.64 | 09/13/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in BBLG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BBLG for Q2 2026. | ||||
BBLG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BBLG ranks across every disease it competes in
Competitive Position is a premium feature
See how BBLG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBBLG News
BBLGBone Biologics Expands Trial Sites
Bone Biologics Corporation has expanded its first-in-human pilot clinical trial of NB1 by adding six hospital sites in Australia. This expansion doubles the number of participating centers, which is anticipated to enhance patient screening and surgical scheduling. The trial aims to evaluate the safety and effectiveness of NB1 in patients with degenerative disc disease, with full enrollment expected by the end of 2026.
Read more →BBLGBone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Bone Biologics Corporation will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Jeff Frelick will conduct one-on-one meetings with investors, and a virtual presentation will be available on-demand starting September 11. The company focuses on regenerative medicine for bone, particularly in spinal fusion procedures.
Read more →BBLG▼ -27.6%on this news
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
Bone Biologics Corporation has successfully extended the validated shelf life of its rhNELL-1 protein to 32 months. This achievement allows for improved manufacturing, storage, and distribution processes as the company prepares for pivotal studies. The extension builds on previous milestones and is expected to enhance overall operational efficiency as the lead product candidate, NB1, progresses through clinical trials.
Read more →BBLGBone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
Bone Biologics Corporation provided a mid-year update highlighting significant progress in 2026, including a successful financing round generating $3.0 million. The company is advancing its first-in-human clinical study for NB1, a bone graft product candidate, and has extended the shelf life of its rhNELL-1 protein to 29 months. The CEO emphasized the importance of executing clinical programs and managing capital effectively.
Read more →BBLG▼ -8.8%on this news
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bone Biologics Corporation has announced a private placement of up to $9.0 million with a single institutional investor. The offering includes common stock and warrants priced at $1.42 per share. Proceeds will be used for clinical trials and corporate purposes. The closing is expected around July 9, 2026, pending customary conditions.
Read more →BBLGBone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
Bone Biologics Corporation has successfully extended the validated shelf life of its rhNELL-1 protein product to 29 months, up from 24 months. This extension is supported by third-party stability data and is expected to improve lot sizing and distribution planning as the company prepares for a pivotal study. The CEO highlighted the operational benefits and increased confidence in the product's formulation.
Read more →BBLGBone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Bone Biologics Corporation has outlined its operational, scientific, and corporate milestones achieved in 2025 and provided an outlook for 2026. Key achievements include the extension of the shelf life of its rhNELL-1 product to 24 months and completion of a $5 million public offering to support its clinical programs. The company also maintained compliance with Nasdaq's listing requirements and expanded its intellectual property portfolio. Looking forward, Bone Biologics aims to continue advancing its clinical-stage programs and strengthen its operational structure.
Read more →BBLG▼ -6.7%on this news· ran to -22% by day 3
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Bone Biologics Corporation has successfully extended the shelf life of its rhNELL-1 product to 24 months, a significant improvement from previous milestones. This extension is backed by ongoing stability data and is expected to enhance manufacturing efficiency and supply-chain flexibility. The company views this achievement as a crucial step toward commercialization and long-term shareholder value creation.
Read more →BBLG▲ +37.7%on this news
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
Bone Biologics Corporation (NASDAQ: BBLG) CEO Jeffrey Frelick issued a letter to stockholders detailing updates on the company's progress and outlook for their lead product, NB1. The letter highlights the anticipation of completing enrollment in a pivotal first-in-human clinical study, which is evaluating NB1's effectiveness in treating degenerative disc disease. Despite slower enrollment than expected, Frelick remains optimistic about NB1's potential to improve spinal fusion outcomes. The company also reported successful funding through a public offering and advancements in the product's shelf life.
Read more →BBLG▲ +10.1%on this news
Bone Biologics Announces Pricing of $5.0 Million Public Offering
Bone Biologics Corporation has announced the pricing of a public offering of 1,250,000 shares at $4.00 each, along with accompanying warrants. The offering is expected to raise gross proceeds of approximately $5.0 million, which the company plans to use to fund clinical trials and bolster its patent portfolio. The closing is anticipated by June 30, 2025, subject to customary conditions. Additional proceeds of up to $10.0 million may be realized if warrants are fully exercised.
Read more →BBLGBone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Bone Biologics Corporation has announced that it has regained compliance with the Nasdaq listing requirements, following a notice indicating its previous non-compliance. The company met the minimum closing bid price requirement of $1.00 for at least 10 consecutive trading days, thereby ensuring its stock will remain listed on the Nasdaq Capital Market. Founded to focus on regenerative medicine for bone, Bone Biologics is actively developing products for spinal fusion and has rights to additional applications in trauma and osteoporosis.
Read more →BBLGBone Biologics Announces 1-for-6 Reverse Stock Split
Bone Biologics Corporation announced a 1-for-6 reverse stock split that will take effect on June 10, 2025. This decision follows stockholder approval for a reverse split within a range of 1-for-2.5 to 1-for-10. After the split, the number of shares held by shareholders will consolidate, but their percentage ownership will remain the same. The company plans to maintain its trading symbol on Nasdaq and aims to stabilize its stock price following the split.
Read more →BBLGBone Biologics Appoints Phillip T. Meikle to its Board of Directors Brings 30+ years of commercial experience in the orthopedic and spine industry BURLINGTON, Mass. (
Bone Biologics Corporation has appointed Phillip T. Meikle to its Board of Directors, effective immediately. Meikle brings over 30 years of experience in the orthopedic and spine industry, having founded and sold an orthopedic distribution company. His appointment follows the retirement of Don R. Hankey from the board, keeping the number of directors at four. The company anticipates that Meikle's extensive knowledge and industry relationships will aid in the development of their product candidate, NB1, for spinal fusion patients.
Read more →BBLGBone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds BURLINGTON, Mass. (
Bone Biologics Corporation has announced a definitive agreement for the exercise of certain existing warrants, resulting in gross proceeds of approximately $2.1 million. The company will issue new unregistered warrants alongside this, aimed at funding clinical trials and maintaining its patent portfolio. The completion of the offering is anticipated to close by August 2, 2024, contingent on customary closing conditions. These developments signal strategic moves to bolster the company's financial footing and support ongoing product development.
Read more →BBLG▼ -14.1%on this news
First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion Reminder: Management "CEO Chat" with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time BUR
Bone Biologics Corporation has treated the first two patients in a pilot clinical study evaluating its NB1 bone graft device for spine fusion. This multicenter study aims to assess the device's safety and efficacy in treating degenerative disc disease. The device combines NELL-1 protein with demineralized bone matrix to promote bone regeneration. The study has received FDA support for potential progression to pivotal trials in the U.S.
Read more →BBLGBone Biologics Announces Pricing of $2.0 Million Public Offering
Bone Biologics Corporation has priced a public offering of approximately 781,251 shares and warrants to purchase the same number of shares at $2.56 each. The gross proceeds from the offering are expected to total around $2.0 million, which the company will utilize to fund clinical trials and maintain its patent portfolio. The offering is subject to customary closing conditions and is expected to close on or about March 6, 2024. The company focuses on orthobiologic products for spine fusion, aiming to advance its development efforts with strategic partners.
Read more →BBLGBone Biologics Reports Progress with NB1 Clinical Program BURLINGTON, Mass. (
Bone Biologics Corporation announced significant progress regarding its NB1 clinical program, having received Human Research Ethics Committee approval for a multicenter pilot clinical trial. The trial will evaluate the safety and effectiveness of NB1 in 30 adult subjects undergoing spinal fusion for degenerative disc disease. The inclusion of rhNELL-1 in the product candidate is expected to support increased bone regeneration, potentially tapping into a multi-billion dollar market for spinal fusion treatments. However, the company acknowledges risks associated with developing its products that could impact outcomes.
Read more →BBLGBone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors Brings 20+ years of experience in finance and business operations at both public and private life sciences companies BURLINGTON, M
Bone Biologics Corporation has appointed Robert E. Gagnon to its Board of Directors, replacing Erick Lucera. Gagnon brings over 20 years of experience in finance and business operations from various life sciences companies, which is anticipated to benefit Bone Biologics, particularly as it prepares for its pilot study with product NB-1. His past roles include positions at Remix Therapeutics, Verastem Oncology, and Biogen Idec, among others. The company is focused on developing orthobiologic products for spine fusion markets and has additional interests in trauma and osteoporosis applications.
Read more →BBLGBone Biologics Regains Compliance with Nasdaq Continued Listing Requirements BURLINGTON, Mass. (
Bone Biologics Corporation has announced that it has regained compliance with the minimum bid price requirement set by Nasdaq, allowing its common stock to remain listed on the Nasdaq Capital Market. The company met the necessary condition by maintaining a closing bid price above $1.00 for ten consecutive trading days as of January 4, 2024. However, it will continue to be monitored by Nasdaq's discretionary panel until June 28, 2024. The company's focus remains on developing regenerative medicine for bone, particularly in spinal fusion procedures and related applications.
Read more →BBLGBone Biologics Announces 1-for-8 Reverse Stock Split
Bone Biologics Corporation announced a 1-for-8 reverse stock split effective December 20, 2023. This action was approved by stockholders on December 12 and aims to potentially improve the company's stock performance. Following the split, every eight shares will combine into one while maintaining stockholders' ownership proportions. The company is focusing on developing orthobiologic products for spine fusion markets, which were built upon preclinical research involving the Nell-1 protein.
Read more →About Bone Biologics Corp
Headquarters2 BURLINGTON WOODS DRIVE,, BURLINGTON, MA, 01803
Founded2004
BIOPHARMAWATCH ELITE PLUS
Trade the next BBLG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime